Ventavis: profile and news

CoTherix Reports First Quarter Results  May 3, 2006
Net product sales from the Company's Ventavis® Inhalation Solution in the first quarter of 2006 were $14.5 million, up 32 percent from $11.0 million in the ... - Yahoo! News (press release)

CoTherix to Webcast Presentation at the Rodman & Renshaw Global ...  May 5, 2006
CoTherix markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of pulmonary arterial hypertension (PAH) in patients with ... - Yahoo! News (press release)

CoTherix Up on Analyst Rating  May 4, 2006
The company booked revenue of $14.5 million from sales of its inhaled pulmonary arterial hypertension treatment Ventavis, up from $345,000 a year ago. ... - Houston Chronicle,

United Therapeutics moves on to ovarian cancer drug, new labs  Apr 27, 2006
...strength. In only nine months of 2005, sales for CoTherix’ Ventavis generate revenues of $23.9 million for the small company. ... - Business Gazette,

CoTherix to Host Conference Call on May 3, 2006, to Announce First ...  Apr 21, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News (press release)